| name | endo-against-vit-d-supp-under-50 |
| description | Recommends against empiric vitamin D supplementation beyond the Dietary Reference Intake (DRI) in adults younger than 50 years. Use when a clinician considers vitamin D supplementation for non‑pregnant adults under 50 without established indications for treatment. |
Against routine vitamin D supplementation in adults under 50
STEP 1 — Gather Information
Record patient age, pregnancy status, and presence of established indications for vitamin D treatment (e.g., hypocalcemia, malabsorption, chronic kidney disease, osteoporosis, or other conditions requiring therapeutic vitamin D).
STEP 2 — Rule In / Rule Out
If the patient is <50 years, non‑pregnant, and has no established indications for vitamin D treatment → proceed to Step 3; otherwise, individualize management based on the identified indication and stop.
STEP 3 — Classify or Stratify
Classify the patient as having no indication for empiric vitamin D supplementation beyond DRI.
STEP 4 — Decide
Recommend against empiric vitamin D supplementation beyond the DRI; advise meeting the DRI (600 IU daily for ages 19‑70, 800 IU for >70) through diet and safe sun exposure; do not order 25(OH)D testing for this purpose.
Clinical Guardrails / Mimics / Pitfalls
Do not initiate high‑dose or intermittent vitamin D regimens for general prevention; avoid routine 25(OH)D screening in this group; remember that supplementation remains appropriate for patients with established indications (e.g., treated osteoporosis, malabsorption syndromes) despite the general recommendation against empiric use.
Concrete Clinical Example
A 35‑year‑old non‑pregnant woman asks whether she should take a 2000 IU vitamin D daily pill for “general health”; she has no osteoporosis, malabsorption, CKD, or other indications. Advise against empiric supplementation beyond the DRI (600 IU daily) and suggest obtaining vitamin D from fortified foods, fatty fish, and sensible sun exposure.
Source: Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2024, DOI: 10.1210/clinem/dgae290
